Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Dicerna PharmaceuticalsMorphicMyovant SciencesGeneration BioPrestige Consumer Healthcare
SymbolNASDAQ:DRNANASDAQ:MORFNYSE:MYOVNASDAQ:GBIONYSE:PBH
Price Information
Current Price$26.09$59.35$18.15$27.20$43.75
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.81.11.31.81.6
Analysis Score3.51.53.33.53.2
Community Score3.02.32.63.82.8
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.00.80.0
Earnings & Valuation Score0.60.00.60.61.9
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$37.83$63.33$31.17$40.60$87.60
% Upside from Price Target45.01% upside6.71% upside71.72% upside49.26% upside100.23% upside
Trade Information
Market Cap$1.99 billion$1.93 billion$1.65 billion$1.53 billion$2.18 billion
Beta1.331.012.99N/A0.76
Average Volume826,527418,360946,502696,524585,040
Sales & Book Value
Annual Revenue$23.90 million$16.98 millionN/AN/A$963.01 million
Price / Sales83.31113.42N/AN/A2.27
CashflowN/AN/AN/AN/A$4.25 per share
Price / CashN/AN/AN/AN/A10.29
Book Value$2.22 per share$4.62 per share($1.21) per shareN/A$23.30 per share
Price / Book11.7512.85N/AN/A1.88
Profitability
Net Income$-120,460,000.00$-43,330,000.00$-288,990,000.00N/A$142.28 million
EPS($1.76)($2.69)($3.37)N/A$2.96
Trailing P/E RatioN/AN/AN/A0.0013.59
Forward P/E RatioN/AN/AN/AN/A13.34
P/E GrowthN/AN/AN/AN/A2.96
Net Margins-88.81%N/AN/AN/A17.03%
Return on Equity (ROE)-71.72%-36.62%N/AN/A13.76%
Return on Assets (ROA)-16.60%-20.69%-201.20%N/A4.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A1.22%
Current Ratio2.62%6.14%1.75%31.19%1.98%
Quick Ratio2.62%6.14%1.75%31.19%1.14%
Ownership Information
Institutional Ownership Percentage80.64%61.49%33.77%63.26%N/A
Insider Ownership Percentage11.30%39.50%3.90%N/A1.20%
Miscellaneous
Employees30289214100520
Shares Outstanding76.32 million32.45 million90.80 million56.43 million49.87 million
Next Earnings Date5/6/2021 (Estimated)5/5/2021 (Estimated)5/17/2021 (Estimated)6/17/2021 (Estimated)5/6/2021 (Confirmed)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
VIVIQ™ Skin Health Launches to Bring Clinical Benefits to Prestige SkincareVIVIQ™ Skin Health Launches to Bring Clinical Benefits to Prestige Skincare
prnewswire.com - April 9 at 7:23 PM
Are Investors Undervaluing Prestige Consumer Healthcare Inc. (NYSE:PBH) By 48%?Are Investors Undervaluing Prestige Consumer Healthcare Inc. (NYSE:PBH) By 48%?
finance.yahoo.com - April 9 at 2:23 PM
Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of "Buy" from BrokeragesPrestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - April 8 at 12:26 PM
Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Investment Research to "Buy"Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Investment Research to "Buy"
marketbeat.com - April 8 at 10:31 AM
Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarter and Year-End Earnings ResultsPrestige Consumer Healthcare Inc. to Release Fiscal 2021 Fourth Quarter and Year-End Earnings Results
finance.yahoo.com - April 8 at 8:34 AM
Heres Why Prestige Consumer Healthcare (PBH) Looks PromisingHere's Why Prestige Consumer Healthcare (PBH) Looks Promising
nasdaq.com - April 6 at 2:16 PM
Prestige Consumer Healthcare Stock Gives Every Indication Of Being Modestly OvervaluedPrestige Consumer Healthcare Stock Gives Every Indication Of Being Modestly Overvalued
finance.yahoo.com - March 29 at 10:53 PM
$230.27 Million in Sales Expected for Prestige Consumer Healthcare Inc. (NYSE:PBH) This Quarter$230.27 Million in Sales Expected for Prestige Consumer Healthcare Inc. (NYSE:PBH) This Quarter
americanbankingnews.com - March 28 at 9:30 AM
Heres Why Prestige Consumer (PBH) Stock Appears PromisingHere's Why Prestige Consumer (PBH) Stock Appears Promising
nasdaq.com - March 9 at 2:22 PM
Moving Average Crossover Alert: Prestige Consumer Healthcare (PBH)Moving Average Crossover Alert: Prestige Consumer Healthcare (PBH)
nasdaq.com - February 18 at 8:30 AM
Prestige Consumer Healthcare Inc. Announces Offering of $500 Million Senior NotesPrestige Consumer Healthcare Inc. Announces Offering of $500 Million Senior Notes
markets.businessinsider.com - February 10 at 7:40 AM
Prestige Brands, Inc. -- Moodys upgrades Prestige Brands CFR to B1; outlook stablePrestige Brands, Inc. -- Moody's upgrades Prestige Brands' CFR to B1; outlook stable
finance.yahoo.com - February 9 at 2:28 PM
Update: Prestige Consumer Healthcare (NYSE:PBH) Stock Gained 25% In The Last Three YearsUpdate: Prestige Consumer Healthcare (NYSE:PBH) Stock Gained 25% In The Last Three Years
finance.yahoo.com - February 8 at 6:45 PM
Prestige Consumer Healthcare Inc. 2021 Q3 - Results - Earnings Call PresentationPrestige Consumer Healthcare Inc. 2021 Q3 - Results - Earnings Call Presentation
seekingalpha.com - February 8 at 2:54 PM
Analysts Conflicted on These Healthcare Names: Cigna (CI), Alexion Pharmaceuticals (ALXN) and Prestige Brand Holdings (PBH)Analysts Conflicted on These Healthcare Names: Cigna (CI), Alexion Pharmaceuticals (ALXN) and Prestige Brand Holdings (PBH)
smarteranalyst.com - February 5 at 12:39 AM
Recap: Prestige Consumer Q3 EarningsRecap: Prestige Consumer Q3 Earnings
benzinga.com - February 4 at 9:38 AM
Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Third Quarter ResultsPrestige Consumer Healthcare Inc. Reports Fiscal 2021 Third Quarter Results
markets.businessinsider.com - February 4 at 9:38 AM
Prestige Brands (PBH) Q3 Earnings and Revenues Beat EstimatesPrestige Brands (PBH) Q3 Earnings and Revenues Beat Estimates
finance.yahoo.com - February 4 at 9:38 AM
Analysts Estimate Prestige Brands (PBH) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Prestige Brands (PBH) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - January 28 at 2:41 PM
Why STAAR Surgical and Prestige Consumer Healthcare Stocks Jumped TodayWhy STAAR Surgical and Prestige Consumer Healthcare Stocks Jumped Today
msn.com - January 26 at 2:14 PM
Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Third Quarter Earnings ResultsPrestige Consumer Healthcare Inc. to Release Fiscal 2021 Third Quarter Earnings Results
finance.yahoo.com - January 8 at 1:11 PM
How Much Does Prestige Consumer Healthcares (NYSE:PBH) CEO Make?How Much Does Prestige Consumer Healthcare's (NYSE:PBH) CEO Make?
finance.yahoo.com - December 24 at 9:25 AM
Is PBH A Good Stock To Buy Now?Is PBH A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 5:40 PM
Why Is Prestige Brands (PBH) Up 8.8% Since Last Earnings Report?Why Is Prestige Brands (PBH) Up 8.8% Since Last Earnings Report?
finance.yahoo.com - December 5 at 5:06 PM
A Trio of Small Caps for the Growth-Oriented InvestorA Trio of Small Caps for the Growth-Oriented Investor
finance.yahoo.com - November 16 at 3:51 PM
Prestige Consumer Healthcare Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearPrestige Consumer Healthcare Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
nasdaq.com - November 9 at 2:31 PM
DateCompanyBrokerageAction
3/8/2021Dicerna PharmaceuticalsChardan CapitalBoost Price Target
3/8/2021Dicerna PharmaceuticalsHC WainwrightBoost Price Target
3/1/2021Dicerna PharmaceuticalsB. RileyBoost Price Target
11/25/2020Dicerna PharmaceuticalsSVB LeerinkLower Price Target
5/12/2020Dicerna PharmaceuticalsRoyal Bank of CanadaInitiated Coverage
5/11/2020Dicerna PharmaceuticalsSunTrust BanksBoost Price Target
3/19/2020Dicerna PharmaceuticalsBerenberg BankInitiated Coverage
3/5/2020Dicerna PharmaceuticalsCitigroupLower Price Target
3/1/2021MorphicWells Fargo & CompanyBoost Price Target
8/26/2020MorphicBMO Capital MarketsReiterated Rating
3/5/2020MorphicCowenReiterated Rating
7/22/2019MorphicJefferies Financial GroupInitiated Coverage
1/6/2021Myovant SciencesThe Goldman Sachs GroupDowngrade
12/21/2020Myovant SciencesRobert W. BairdBoost Price Target
6/23/2020Myovant SciencesEvercore ISIBoost Price Target
6/1/2020Myovant SciencesJPMorgan Chase & Co.Boost Price Target
11/19/2019Myovant SciencesJMP SecuritiesReiterated Rating
2/13/2019Myovant SciencesBarclaysUpgrade
3/1/2021Generation BioWilliam BlairInitiated Coverage
2/25/2021Generation BioNeedham & Company LLCInitiated Coverage
7/7/2020Generation BioWedbushInitiated Coverage
11/9/2020Prestige Consumer HealthcareCIBCBoost Price Target
11/6/2020Prestige Consumer HealthcareTD SecuritiesBoost Price Target
11/6/2020Prestige Consumer HealthcareDA DavidsonLower Price Target
6/29/2020Prestige Consumer HealthcareSidotiUpgrade
6/17/2020Prestige Consumer HealthcareOppenheimerReiterated Rating
2/13/2019Prestige Consumer HealthcareDesjardinsDowngrade
1/15/2019Prestige Consumer HealthcareRaymond JamesDowngrade
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.